DISCOVER OUR PIONEERING CONTRIBUTIONS TO ONCOLOGY THROUGH PRESTIGIOUS JOURNALS AND PLATFORMS LIKE ASCO, ESMO, AND SABCS. ELEVATE YOUR INSIGHTS WITH OUR CUTTING-EDGE CLINICAL TRIAL PUBLICATIONS.
EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT
PUBLICATIONS
THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.
STUDY
OFFICIAL TITLE
DISEASE
JOURNAL/
CONGRESS
YEAR
DOWNLOAD
PRIMED
Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients (pts) with triple-negative or HR+/HER2- advanced breast cancer (ABC; PRIMED): A phase 2 trial.
BREAST
ASCO
2024
RESPONSE
Clinicopathological and Molecular Predictors of [18F]FDG-PET Disease Detection in HER2-Positive Early Breast Cancer: RESPONSE, a substudy of the randomized PHERGain Trial
BREAST
Eur J Nucl Med Mol Imaging
2024
PARSIFAL
Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer
BREAST
(Journal) The Breast
2024
PECATI
PECATI: A phase 2 trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma
THYMIC
ESMO
2024
ZZ-FIRST
First results from ZZFIRST: a randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC)
PROSTATE
ESMO
2024
PHERGAIN
SUBSTUDY - Trop-2: Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab
BREAST
Breast Cancer Research and Treatment
2024
PHERGAIN
SUBSTUDY - HER2DX: HER2DX Genomic Assay in HER2-positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from PHERGain Phase II Trial
BREAST
Clinical Cancer Research
2024
CALADRIO
Profiling the gut and oral microbiota of hormone-receptor positive, HER2-negative metastatic breast cancer patients receiving pembrolizumab and eribulin
BREAST
(Journal) Microbiome Research Reports
2024
NOBROLA
A Two-stage Simon Design Phase II Study of Single Agent Olaparib for Non-BRCA MBC Patients With HRD
BREAST
(Journal) The Breast
2024
DEBBRAH
Trastuzumab Deruxtecan in Patients with Central Nervous System Involvement from HER2-Positive Breast Cancer: The DEBBRAH Trial
BREAST
(Journal) Neuro-Oncology
2023
I3LUNG
The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
LUNG
(Journal) Clinical Lung Cancer
2023
PHERGAIN
3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC)
BREAST
ASCO
2023
Other MEDSIR related articles
